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IFN induction of the
antiviral factor IFITM3
in humans
Interferon (IFN) induced trans-membrane
protein 3 (IFITM3) has been shown to
restrict replication of around seventeen,
mostly enveloped, RNA viruses includ-
ing influenza A virus (IAV), HIV-1, Ebola,
SARS coronavirus, and Dengue virus
[1, 2]. The tropism of these viruses is
highly varied; HIV-1 predominantly infects
CD4+ T cells, IAV predominantly epithelial
cells of the respiratory system and Dengue
virus can infect skin and Langerhans cells.
The mechanisms of IFITM3-mediated
viral restriction have yet to be determined.
Investigations into IFITM3 restriction have
been hindered by a lack of antibodies spe-
cific to IFITM3 as most commercially avail-
able antibodies cross-react to the closely
related homolog IFITM2.
We custom-generated an IFITM3-
specific antibody with minimal cross-
reactivity to IFITM2 [3]. Using this anti-
body and CRISPR-generated IFITM3−/−
human cell lines, we found differences
in basal expression of IFITM3 across
several cell lines, with IFITM3 expression
decreasing following differentiation of
induced pluripotent stem cells (iPSC)
into macrophages (iPSC-Mac), in line
with previous reports [4] (Supporting
Information Fig. S1).
Investigation into the basal expression
pattern of IFITM3 in primary human sam-
ples revealed differences across immune
cell subsets. There was a consistent pattern
of higher expression in myeloid compared
to lymphoid cells in adult blood sam-
ples (p = 0.0202), lung para-tumor tissue
(p = 0.0007), and cord blood samples (p
= 0.0175; Fig. 1A).
IFITM3 was highest in CD16+ mono-
cytes from adult blood (Fig. 1B), while
expression in the lung was highest in gran-
ulocyte populations (Fig. 1C). The lung
para-tumor samples allowed us to inves-
tigate the expression of IFITM3 in lung
epithelial cells, most likely type 1 and 2
pneumocytes, however we were unable to
identify ciliated epithelial cells as these
are present higher up the respiratory tract,
preventing direct comparison to previous
mouse models [5].
In cord blood samples, IFITM3 expres-
sion was highest in hematopoietic stem
cells (HSC) in accordance with previ-
ous suggestions [4]. However, the high
expression in CD16+ monocytes in these
samples suggests that it is not as sim-
ple as increased differentiation leading to
reduced expression compared to HSC.
The pattern of expression across
immune cell subsets was not shared
by other IFN-stimulated genes (ISG)
investigated here, STAT1 or BST2, that
are also involved in antiviral responses
[6, 7] (Supporting Information Fig. S2).
However, there was higher expression in
myeloid compared to lymphoid cells for
both proteins.
As an ISG, IFITM3 has previously been
shown to be induced by both type I and
type II IFNs in a murine setting [5]. We
stimulated HEK293 and A549 human cell
lines with 0–10,000 U/mL IFN for 24 h
and measured IFITM3 expression by west-
ern blot (Supporting Information Fig. 3).
We saw strong responses to type I IFNs but
a much weaker response to type II and III
IFNs, with some differences across the two
cell lines.
In primary immune cells, there was
some induction with type I IFN but min-
imal response to other types of IFN and
these results were not significant (Fig. 2A).
When the immune cells were separated
into myeloid and lymphoid cells there was
again a strong induction with type I IFN
in myeloid cells (p = 0.0449) by IFN-α,
but negligible increases were seen in the
lymphoid compartment (Fig. 2B). After 48
h IFN stimulation there was no measur-
able increase in STAT1 or BST2 suggest-
ing that these proteins had already peaked
and returned to baseline levels by 48 h
(data not shown).
Myeloid cells can induce greater than
twofold induction with type I IFN, with the
exception of CD16+ monocytes (Fig. 2C).
CD16+ monocytes have high basal expres-
sion, suggesting that they are already
expressing maximal levels of IFITM3. In
contrast, we see minimal induction of
IFITM3 in lymphoid immune cell subsets
(Fig. 2C). NK and B cells show a mod-
est increase in expression following type
I IFN stimulation. Neither T cell popula-
tions show any increase in IFITM3 expres-
sion (Fig. 1B), confirming murine studies
showing that only CD3/CD28 activation
increased IFITM3 expression [8].
Plasmacytoid dendritic cells (pDC)
responded with approximately three-
fold induction following type III IFN
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Figure 1. Basal IFITM3 expression varies in primary human cells. IFITM3 expression was measured in primary human samples using CyTOF. (A)
Results from adult blood, lung para-tumor tissue and cord blood samples. Expression in myeloid and lymphoid cells was compared by paired t-test.
(B) Basal IFITM3 expression in human adult blood samples shown by individual cell types. (C) Basal IFITM3 expression in human lung para-tumor
tissue shown by individual cell types. (D) Basal IFITM3 expression in human cord blood samples shown by individual cell types. HSC, hematopoietic
stem cells; MPP, multipotent progenitor; LMPP, lymphoid-primed multipotent progenitors; MLP, multi-lymphoid progenitor; MEP, megakaryocyte
erythroid progenitor; CMP, common myeloid progenitor; GMP, granulocyte-monocyte progenitors; B/NK Pro, B cell + NK cell progenitor. Data are
expressed ±SEM with mean center values. Adult blood donors n = 3, one experiment, lung tissue samples n = 5, four independent experiments,
Cord blood samples n = 3, three independent experiments.
stimulation. These are the only immune
cell subset to express the IFN-λ receptor,
IFNLR1, showing that type III IFN can also
induce IFITM3 strongly if the receptor is
present [9].
The basal expression of IFITM3 is
inconsequential if new protein can be
induced rapidly during an infection. We
found that induction of IFITM3 was not
rapid and instead it took ∼36 h to reach
maximal IFITM3 expression (Supporting
Information Fig. S4). Looking into the
timescale of IFITM3 induction in primary
cells, we found that expression was high-
est at 48 h post IFN stimulation in CD14+
monocytes (Fig. 2D).
These results show that basal expres-
sion of IFITM3 can vary across immune
cell subsets, with consistently higher
expression on myeloid cells compared to
lymphoid. In the myeloid compartment,
low basal expression can be overcome
by strong type I IFN induction. However,
in the lymphoid compartment, there is
minimal induction by IFN suggesting that
IFITM3 does not play a strong role in
viral restriction in these cell types. Know-
ing that it takes at least 24 h for IFITM3
to be induced strongly by IFN stimula-
tion highlights the importance of basal
expression in the early stages of a viral
infection.
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Figure 2. IFN induction of IFITM3 in primary human cells. (A) Expression of IFITM3 was measured by CyTOF in primary human cells from adult
blood samples (n = 3) following 48-h stimulation with 100 U/mL IFN. (B) Expression of IFITM3 in myeloid and lymphoid cells in adult blood samples
following 48-h stimulation with 100 U/mL IFN. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test, comparing all IFN stim-
ulations to the no IFN control. (C) Fold change in IFITM3 expression following 48-h stimulation with 100 U/mL IFN compared to no IFN controls.
(D) Flow cytometry plots showing expression of IFITM3 in primary human monocytes (CD14+) following up to 72-h stimulation with 500 U/mL IFN.
(E) IFITM3 expression measured by flow cytometry compared to expression 72-h post IFN stimulation. Data are expressed ±SEM with mean center
values. IFN stimulation of adult blood donors n = 3, one experiment. Monocyte time-course n = 3, three independent experiments.
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